| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 3.2 | 2.9 |
| Gross profit | 1.1 | 1.2 |
| Profit before tax | -1.1 | -0.6 |
| Net income | -1.1 | -0.7 |
| EPS (diluted, $ a share) | $-2.28 | $-1.64 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +8.4% |
|---|---|
| Gross margin | 35.4% |
| Operating margin | -79.9% |
10-Q filed with the SEC, NASDAQ: NXGL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Nexgel, Inc.: key numbers
- Share price
- $3.93Close, Nov 16
- Market cap
- $2.11M
- Shares outstanding
- 536.11KLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Nexgel, Inc.
All →Nexgel Interim CEO Brian Joseph Kieser Buys $733K of Stock
Brian Joseph Kieser, Interim CEO, bought 133,216 shares of Nexgel, Inc. at $5.50 a share, worth $733K in total on Nov 10, 2026. Shares held after the trade: 133,216.
- Value
- $733K
- Shares
- 133,216
- Price
- $5.50
- Role
- Interim CEO
- Trade date
- Nov 10, 2026
Nexgel Insider steven mark glassman Buys $25K of Stock
steven mark glassman bought 4,546 shares of Nexgel, Inc. at $5.50 a share, worth $25K in total on Nov 10, 2026. Shares held after the trade: 12,379 (+58.0%).
- Value
- $25K
- Shares
- 4,546
- Price
- $5.50
- Holding change
- +58.0%
- Trade date
- Nov 10, 2026
Nexgel M&A Deal with Fountainhead LifeSciences
NEXGEL announced a strategic recapitalization and update on a potential merger with Fountainhead LifeSciences, including its affiliates Sequence LifeScience and NVISION Biomedical Technologies. As part of the plan, holders of $14.125 million in convertible notes (95% of outstanding principal) agreed to convert their debt into common stock at $5.50 per share, contingent upon the completion of the merger.
- Counterparty
- Fountainhead LifeSciences
Nexgel Reverse Stock Split
NexGel, Inc. has announced a 1-for-20 reverse stock split of its common stock, effective October 12, 2026. The split aims to consolidate every twenty shares into one share to adjust the per-share trading price while maintaining the par value at $0.001. The common stock will continue to trade on The Nasdaq Capital Market under the ticker 'NXGL' with a new CUSIP number.
Nexgel Investor Presentation
NexGel, Inc. has released a new shareholder update presentation titled 'Strategic Review & Proposed Platform Reorganization.' The presentation outlines the company's strategic direction and proposed changes to its business platform to drive future growth.
Nexgel Reverse Stock Split
NexGel stockholders approved an amendment to the Certificate of Incorporation to effect a discretionary reverse stock split at a ratio between 1-for-2 and 1-for-20. Stockholders also approved increasing the number of authorized shares of common stock from 25 million to 150 million.
- Term
- within one year